Using Fractionated Stereotactic Radiotherapy for Pituitary Macroadenomas
Author Information
Author(s): Elhateer H. MD, Muanza T. MD, Roberge D. MD, Ruo R. MSc, Eldebawy E. MD, Lambert C. MD, Patrocinio H. MSc, Shenouda G. MD, Souhami L. MD
Primary Institution: McGill University Health Center
Hypothesis
The application of fractionated stereotactic radiotherapy (fsrt) to pituitary tumours is aimed at reducing toxicity through improved dose conformality and reduced treatment margins.
Conclusion
Fractionated stereotactic radiotherapy is safe and effective in managing large pituitary macroadenomas.
Supporting Evidence
- All patients had a local control rate of 100% after treatment.
- One patient achieved a complete clinical response.
- Treatment was well tolerated with no significant acute effects.
Takeaway
Doctors used a special type of radiation treatment to help patients with big tumors in their pituitary glands, and it worked really well without causing bad side effects.
Methodology
Thirteen patients with pituitary macroadenomas underwent fsrt after surgical resection, receiving a median dose of 50.4 Gy in 1.8-Gy fractions over 5.5 weeks.
Limitations
The study had a small sample size and relatively short follow-up period.
Participant Demographics
The participants included 9 men and 4 women with a median age of 56 years.
Want to read the original?
Access the complete publication on the publisher's website